RAD51 GENOTYPE AND TRIPLE-NEGATIVE BREAST CANCER (TNBC) RISK IN POLISH WOMEN

被引:22
|
作者
Smolarz, Beata [1 ]
Zadrozny, Marek [2 ]
Duda-Szymanska, Joanna [1 ,3 ]
Makowska, Marianna [4 ]
Samulak, Dariusz [5 ,6 ,7 ]
Michalska, Magdalena M. [5 ]
Mojs, Ewa [8 ]
Brys, Magdalena
Forma, Ewa [9 ]
Romanowicz-Makowska, Hanna [1 ]
机构
[1] Inst Polish Mothers Mem Hosp, Dept Pathol, Mol Genet Lab, PL-93338 Lodz, Poland
[2] Inst Polish Mothers Mem Hosp, Dept Oncol, PL-93338 Lodz, Poland
[3] Med Univ Lodz, Dept Pathol, Lodz, Poland
[4] Reg Hosp, Lodz, Poland
[5] Reg Hosp, Dept Obstet & Gynaecol, Kalisz, Poland
[6] Poznan Univ Med Sci, Cathedral Mothers & Childs Hlth, Poznan, Poland
[7] Poznan Univ Med Sci, Clin Gynaecol Surg, Poznan, Poland
[8] Poznan Univ Med Sci, Dept Clin Psychol, Poznan, Poland
[9] Univ Lodz, Dept Cytobiochem, PL-90131 Lodz, Poland
关键词
triple-negative breast cancer; RAD51; gene; single nucleotide polymorphism; SINGLE NUCLEOTIDE POLYMORPHISMS; RECOMBINATION REPAIR GENES; DNA-REPAIR; HOMOLOGOUS RECOMBINATION; ASSOCIATION; SUSCEPTIBILITY; XRCC3;
D O I
10.5114/PJP.2013.34602
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The most lethal damage for the cell among all damage is double-strand breaks (DSB) of DNA. DSB cause development of cancer diseases including the triple-negative molecular subtype of breast cancer. The aim of this work was to evaluate the single nucleotide polymorphism -135G>C (rs1801320) of the RAD51 gene encoding DNA repair proteins by homologous recombination (HR) in triple-negative breast cancer (TNBC). We assessed the RAD51 -135G>C polymorphism in 50 women with triple-negative breast cancer and in 50 women from the control group. RAD51 polymorphism was analysed by the PCR-RFLP (restriction fragment length polymorphism) technique. Our results demonstrated a significant positive association between the RAD51 C/C genotype and TNBC, with an adjusted odds ratio (OR) of 5.95 (p = 0.002). The homozygous C/C genotype was found in 68% of breast cancer cases and 20% of controls. The variant 135C allele of RADS/increased TNBC risk. This is the first study linking single nucleotide polymorphisms of the RAD51 gene with TNBC incidence in the population of Polish women. In conclusion, RAD51 polymorphisms may be regarded as predictive factors of triple-negative breast cancer in the female population. Large studies are needed to confirm our findings.
引用
下载
收藏
页码:39 / 43
页数:5
相关论文
共 50 条
  • [31] Immune characteristics of triple-negative breast cancer (TNBC) in Latin American women from Colombia
    Zavala, Valentina A.
    Carrasquilla, Laura C.
    Serrano-Gomez, Silvia J.
    Sanabria-Salas, Maria C.
    Baddoo, Melody C.
    Garai, Jone
    Zabaleta, Jovanny
    Fejerman, Laura
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [32] The outcome of special histologic types of triple-negative breast cancer (TNBC).
    Pogoda, Katarzyna
    Niwinska, Anna
    Murawska, Magdalena
    Olszewski, Wojciech
    Nowecki, Zbigniew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
    Lee, Jieun
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [34] Discovery of a small molecule inhibitor for triple-negative breast cancer (TNBC)
    Saran, Uttara
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Singh, Amandeep
    Ankem, Murali K.
    Sharma, Arun K.
    Damodaran, Chendil
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review
    Tajbakhsh, Amir
    Rivandi, Mandi
    Abedini, Soheila
    Pasdar, Alireza
    Sahebkar, Amirhossein
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 140 : 17 - 27
  • [36] Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
    Cho, Eun Yoon
    Chang, Myung Hee
    Choi, Yoon La
    Lee, Jeong Eon
    Nam, Seok Jin
    Yang, Jung-Hyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Im, Young-Hyuck
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 753 - 761
  • [37] Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
    Eun Yoon Cho
    Myung Hee Chang
    Yoon La Choi
    Jeong Eon Lee
    Seok Jin Nam
    Jung-Hyun Yang
    Yeon Hee Park
    Jin Seok Ahn
    Young-Hyuck Im
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 753 - 761
  • [38] Inducing cell state transitions in triple-negative breast cancer (TNBC).
    Loo, Ser Yue
    Toh, Liping
    Pathak, Elina
    Tan, Wilson
    Ma, Siming
    Yuan, Ju
    Periyasamy, Giridharan
    Torta, Federico
    Chan, Jack
    Tan, Tira
    Sim, Yi Rong
    Tan, Veronique
    Tan, Benita
    Madhukumar, Preetha
    Yong, Wei Sean
    Ong, Kong Wee
    Wong, Chow Yin
    Wenk, Markus R.
    Foo, Roger
    Yap, Yoon-Sim
    Lim, Elaine
    Tam, Wai Leong
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 73 - 73
  • [39] Triple-negative breast cancer (TNBC) risk with pathogenic variants (PV) in hereditary cancer predisposition genes
    Hall, Michael J.
    Rosenthal, Eric
    San Roman, Susana
    Bernhisel, Ryan
    Kidd, John
    Hughes, Elisha
    Slavin, Thomas
    Kurian, Allison
    CANCER RESEARCH, 2021, 81 (04)
  • [40] Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
    Cardillo, Thomas M.
    Mostafa, Ali A.
    Rossi, Diane L.
    Liu, Donglin
    Chang, Chien-Hsing
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77